Cargando…

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients

INTRODUCTION: Elderly patients are the most affected and vulnerable to COVID-19 and effective therapeutic interventions are urgently required. We clarified the safety and efficacy of Paxlovid in the treatment of elderly patients with coronavirus disease 2019 (COVID-19). METHODS: Patients aged over 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weng, Chengzhao, Xie, Rongcheng, Han, Guanjie, Yuan, Ya, Li, Shiqin, Wang, Chao, Wang, Xiaofeng, Jiang, Wei, Jiang, Libo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875765/ https://www.ncbi.nlm.nih.gov/pubmed/36696068 http://dx.doi.org/10.1007/s40121-023-00760-x

Ejemplares similares

The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial
por: Zhong, Weijie, et al.
Publicado: (2022)

Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
por: Zhang, Liulu, et al.
Publicado: (2022)

Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
por: Li, Yixian, et al.
Publicado: (2023)

Experience Using Paxlovid for Patients With Coronavirus Disease 2019 in a Resource-Limited Emergency Department
por: Nene, Rahul V., et al.
Publicado: (2022)

The Path to Paxlovid
por: Halford, Bethany
Publicado: (2022)

Croup during the Coronavirus Disease 2019 Omicron Variant Surge
por: Tunҫ, Emine M., et al.
Publicado: (2022)

Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023)

The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2
por: Park, Hanul, et al.
Publicado: (2022)

Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022
por: Kim, Jong Mu, et al.
Publicado: (2023)

The future of Paxlovid for COVID-19
por: Burki, Talha
Publicado: (2022)

Ranolazine Toxicity Secondary to Paxlovid
por: Casey, Bradley, et al.
Publicado: (2023)

Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient
por: Shah, Aaisha, et al.
Publicado: (2022)

PB1969: PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND CORONAVIRUS DISEASE 2019 IN THE OMICRON ERA
por: Qi, Feiyang, et al.
Publicado: (2023)

The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study
por: Yan, Gangfeng, et al.
Publicado: (2022)

Paxlovid™ jetzt direkt an Patienten abgeben
por: Zimmermann, Gerd W.
Publicado: (2022)

Paxlovid-Induced Symptomatic Bradycardia and Syncope
por: Ganipisetti, Venu M, et al.
Publicado: (2023)

CARDIOGENIC SHOCK DUE TO PAXLOVID INTERACTION
por: Enstrom, Cate, et al.
Publicado: (2023)

Serotonin Syndrome Precipitated by Paxlovid Initiation
por: Nasser, Nicholas G, et al.
Publicado: (2023)

COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period
por: Wang, Lindsey, et al.
Publicado: (2022)

Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment
por: Ngonghala, Calistus N., et al.
Publicado: (2023)

Decreased Risk of Coronavirus Disease 2019–Related Hospitalization Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2
por: Ridgway, Jessica P, et al.
Publicado: (2022)

Coronavirus disease 2019 transmission and symptoms in young children during the severe acute respiratory syndrome coronavirus 2 Delta variant and Omicron variant outbreaks
por: Akaishi, Tetsuya, et al.
Publicado: (2022)

Risks of paxlovid in a heart transplant recipient
por: Stawiarski, Kristin, et al.
Publicado: (2023)

Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
por: Marzi, Mahrokh, et al.
Publicado: (2022)

Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid
por: Philipponnet, Carole, et al.
Publicado: (2022)

A Rare Case of Paxlovid-Induced Pancreatitis
por: Zaidi, Syed Muhammad Hussain, et al.
Publicado: (2023)

RNA loads of severe acute respiratory syndrome coronavirus 2 in patients with breakthrough coronavirus disease 2019 caused by the Delta and Omicron variants
por: de Michelena, Paula, et al.
Publicado: (2023)

Why Does the Omicron Variant Largely Spare Olfactory Function? Implications for the Pathogenesis of Anosmia in Coronavirus Disease 2019( )
por: Butowt, Rafal, et al.
Publicado: (2022)

Increased Secondary Attack Rates among the Household Contacts of Patients with the Omicron Variant of the Coronavirus Disease 2019 in Japan
por: Ogata, Tsuyoshi, et al.
Publicado: (2022)

Risk factors and prognosis for coronavirus disease 2019 among 131 hemodialysis patients during the Omicron variant epidemic
por: Wen, Wen, et al.
Publicado: (2023)

2355. Incidence of Omicron Variant Reinfection and Reduction of Reinfection Risk After Coronavirus Disease 2019 Vaccination in Children
por: Ikuse, Tatsuki, et al.
Publicado: (2023)

Coronavirus Disease 2019: Coronaviruses and Blood Safety
por: Chang, Le, et al.
Publicado: (2020)

Viral load kinetics of the severe acute respiratory syndrome coronavirus 2 Omicron variant in children aged 0 to 3 years and their parents
por: Zhou, Jianguo, et al.
Publicado: (2023)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
por: Qiu, Chaochao, et al.
Publicado: (2023)

Coagulopathy in elderly patients with coronavirus disease 2019
por: Yuan, Xueting, et al.
Publicado: (2020)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Computational prediction of interactions between Paxlovid and prescription drugs
por: Kim, Yeji, et al.
Publicado: (2023)

Paxlovid for hospitalized COVID-19 patients with chronic kidney disease
por: Cai, Hong, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study
por: Malahe, S Reshwan K, et al.
Publicado: (2022)

A Comparison of Clinical Presentations in Coronavirus Disease 2019 Caused by Different Omicron Variants in Japan: A Retrospective Study
por: Hirama, Ryutaro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_il911g317g7caladpsnk2nb1po